Dataset opportunity
Azafaros — 医疗影像数据集机会
Azafaros 持有的中等规模医疗影像数据集，可用于诊断 AI 和计算机视觉。
Score
64.1
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
44%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market
全球诊断 AI 市场在 2024 年估值为 15 亿美元，预计复合年增长率为 21.5%（2025-2034 年）。[4]
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-07-27
Why Aidoc is taking a generative AI device to the FDA
medtechdive.com ↗ - 📰press2026-07-27
Carsten Linnemann wird Bundesgesundheitsminister
devicemed.de ↗ - 📰press2026-07-24
Why the FDA’s top spot could sit empty for months
medtechdive.com ↗ - 📰press2026-07-24
Un nuovo traguardo per Encaplast®: ottenuta la certificazione ISCC PLUS (International Sustainability and Carbon Certification)
distrettobiomedicale.it ↗ - 📰press2026-07-24
IP Pills di Bugnion Spa: “Il valore invisibile delle ricerche brevettuali: perché l’informazione viene prima dell’innovazione”
distrettobiomedicale.it ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
医疗影像数据集
Modality
影像
Sector
医疗保健
Volume
中等
Freshness
实时
Rarity
高（专有）
Accessibility
受限
Legal
公司所有 — GDPR 敏感（PII 审查）
Buyer persona
医疗 AI 和诊断影像公司
Azafaros 持有其 RAINBOW、NAVIGATE 和 PRONTO 临床试验中的高价值医疗影像数据集，其中包括 `medical_records` 和 `event_streams` 支持的影像模态。这种结构化的、源自试验的数据非常适合开发和验证诊断 AI 算法，为专注于罕见代谢性疾病的机器学习模型提供高质量、一致且相关的数据输入。
该数据的商业价值体现在快速扩张的全球诊断 AI 市场，该市场在2024 年估值为 15 亿美元，预计到 2034 年将以21.5% 的复合年增长率增长。[4] 尽管由于GDPR 和临床试验法规下的高度敏感患者数据存在访问复杂性，但该数据集对于药物开发的稀缺性和战略重要性使其成为寻求决定性竞争优势的 AI 买家的引人注目的资产。[4] ⚠ 尽职调查（有价值的数据，可协商的访问权限）：高度敏感的患者健康数据受严格的 GDPR 和临床试验法规约束；数据与特定的临床试验方案（RAINBOW、NAVIGATE、PRONTO）相关联；临床数据的二次使用需要特定的患者同意和伦理委员会批准；数据对于药物开发具有极高的战略价值，因此公司对其资产进行保护。· 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 Azafaros 持有来自正式临床试验的专有数据集，这些试验专注于罕见的、经基因确认的神经系统疾病。这包括针对 GM1/GM2 神经节苷脂病和尼曼匹克病等疾病的高价值医疗影像和患者数据。对于医疗 AI 和诊断影像公司而言，这些稀缺数据是构建和验证新型诊断 AI 算法的关键资产。在全球诊断 AI 市场预计每年增长超过 21% 的情况下，访问此类关于罕见病的独特、试验级数据可提供显著且可防御的竞争优势。
See dimension details ↓- Dataset Specificity78
主导的 'medical_records'，医疗保健行业，2 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity70
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
实时/流式传输
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
适用于诊断 AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
买家需求极高，这得益于快速增长的诊断 AI 市场，预计该市场将以 21.5% 的复合年增长率扩张。[4]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/受监管
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
高难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength53
2 种证据类型，3 个命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
所有权=拥有，许可=gdpr_敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 个数据胃口信号（0 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高，5 个近期外部信号 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ 良好目标 — Azafaros 是一家临床阶段的生物制药中小型企业，其核心业务是开发罕见病疗法；在此过程中产生的临床试验数据，包括医疗影像，是一个有价值的副产品，使其成为理想的目标。
- Deep Qualification90
✓ 通过 — 该目标是一家开发罕见神经系统疾病药物的临床阶段公司；它不销售数据。[9, 10, 11] 它持有高价值的临床试验数据，包括可能的医疗影像，作为其核心研发活动的副产品。[1, 15, 16] 然而，这些数据是高度敏感的患者信息，受严格的 GDPR 和临床试验法规约束，使得二次访问极其复杂，并取决于特定的患者同意和伦理批准。[5, 7, 8]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
这些证据证实了来自正式临床试验的结构化数据的存在，包括一项 III 期研究，该研究与经基因确认的罕见神经系统疾病患者队列相关。
Event streams
这一信号表明收集了临床研究的时间序列视频数据，这对于旨在监测和量化疾病进展的 AI 模型非常有价值。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Coverage
Scanned sources
Deliverable
Premium dataset report
Azafaros Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Diagnostics market was valued at $1.5 billion in 2024, with a projected CAGR of 21.5% (2025-2034). [4]. Investment score 64.1/100 (confidence 0.44). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Implicity — 传感器遥测数据集机会
View opportunity →移动出行Zeplug — 移动遥测数据集商机
View opportunity →移动出行Agilenville — 移动遥测数据集商机
View opportunity →